The extract is marketable to consumers looking to address mental fatigue, reaction times and performance
IFF Health has released recent clinical trial data on its Neuravena green oat extract, a nootropic aimed at supporting improved mental processing and resilience to mental fatigue.
In the most recent of seven proprietary clinical studies, the ingredient reportedly demonstrated improvements in brain activity based on electroencephalogram (EEG) measurements during task performance. Benefits were evident after 60 minutes in a young adult population, with participants exhibiting faster and sustained performance.
The extract is marketable to consumers looking to address mental fatigue, reaction times and performance, the company says, including students and esports enthusiasts.
The company's broader brain health platform includes Howard Calm, a probiotic strain demonstrated to reduce perceived stress and promote mental and physical wellbeing, as well as Sharp-PS, an ingredient derived from naturally occurring phospholipids which balances mood and improves mental wellbeing.
“Mental well-being has never been more important and will continue to expand the brain health supplements market. This is why we’re committed to continuous research and development in this space,” said Stephanie Udell, Global Product Launch Leader, IFF Health. “With our broad portfolio and ongoing innovation, alongside decades of technical expertise, we’re well positioned to propel customers, and the industry forward.”